leadf
logo-loader
viewTodos Medical Ltd.

Todos Medical reports $3.2m in sales for month of November, developing 3CL protease diagnostic test

Todos Medical Ltd (OTCQB:TOMDF) CEO Gerald Commissiong tells Proactive the group reported $3.2 million in sales for November 2020, up 269% from October 2020. Commissiong says Todos is now focused on expanding testing offerings to existing clients with novel assays that are complementary to PCR testing.

He says one of the key tests the group expects to bring to the market is its development-stage lab-based 3CL protease diagnostic test that is being advanced to determine whether a PCR positive patient remains contagious to infecting others.

Quick facts: Todos Medical Ltd.

Price: 0.0435 USD

OTCQB:TOMDF
Market: OTCQB
Market Cap: $8.78 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Todos Medical Ltd. named herein, including the promotion by the Company of Todos Medical Ltd. in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Todos Medical receives a $3.4 million strategic investment from Yozma Group...

Todos Medical Ltd. (OTCQB:TOMDF) CEO Gerald Commissiong tells Proactive the in vitro diagnostics company has received a $3.4 million strategic investment from tech-focused venture capital firm Yozma Group Korea. Commissiong says Todos intends to use the proceeds from the Investment...

on 01/25/2021

2 min read